VAERS reports by lot
GSK Flu lot 9K7E4: VAERS reports
24 VAERS reports list lot 9K7E4 as a GSK Flu vaccine, received between 2016-10-04 and 2017-05-16. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).
Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
24
Reports
25%
Marked serious
1
With a death outcome
6
Months with reports
Symptom categories in these reports
A report can mention several categories, so the counts add up to more than the number of reports.
| Category | Count | % |
|---|---|---|
| Injection-site / Local reaction | 23 | 32% |
| General / Systemic (non-local) | 15 | 21% |
| Neurological | 9 | 12% |
| Allergic / Anaphylactic | 6 | 8% |
| Musculoskeletal | 5 | 7% |
| Dermatological (non-injection-site) | 5 | 7% |
| Psychiatric / Neuropsychiatric | 5 | 7% |
| Cardiac / Cardiovascular | 2 | 3% |
| Respiratory | 2 | 3% |
Where reports came from
U.S. state of the reporter, where given (top 12).
| Washington | 3 |
| Virginia | 3 |
| Minnesota | 3 |
| Texas | 2 |
| California | 2 |
| Maryland | 1 |
| Utah | 1 |
| North Carolina | 1 |
| Oregon | 1 |
| Oklahoma | 1 |
| Montana | 1 |
| Idaho | 1 |
Reports by month received
| 2016-10 | 8 | |
| 2016-11 | 10 | |
| 2016-12 | 3 | |
| 2017-02 | 1 | |
| 2017-03 | 1 | |
| 2017-05 | 1 |
Products recorded with this lot
- Influenza (quadrivalent) — Glaxosmithkline Biologicals (24 reports)
Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.
Related
Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.